GSA Capital Partners LLP Reduces Holdings in Monte Rosa Therapeutics, Inc. $GLUE

GSA Capital Partners LLP cut its stake in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) by 53.0% in the third quarter, Holdings Channel.com reports. The fund owned 133,455 shares of the company’s stock after selling 150,357 shares during the quarter. GSA Capital Partners LLP’s holdings in Monte Rosa Therapeutics were worth $989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the stock. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Monte Rosa Therapeutics in the 3rd quarter valued at about $379,000. Squarepoint Ops LLC acquired a new position in Monte Rosa Therapeutics during the second quarter worth approximately $803,000. Allspring Global Investments Holdings LLC purchased a new stake in Monte Rosa Therapeutics in the third quarter valued at approximately $182,000. Bailard Inc. purchased a new stake in Monte Rosa Therapeutics in the second quarter valued at approximately $101,000. Finally, Los Angeles Capital Management LLC acquired a new stake in shares of Monte Rosa Therapeutics in the second quarter valued at approximately $89,000. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Stock Up 4.8%

Shares of NASDAQ:GLUE opened at $19.16 on Friday. Monte Rosa Therapeutics, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $25.77. The firm’s 50-day simple moving average is $19.63 and its 200-day simple moving average is $12.96. The company has a market cap of $1.25 billion, a price-to-earnings ratio of 59.88 and a beta of 1.61.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the transaction, the chief executive officer owned 618,937 shares in the company, valued at approximately $14,538,830.13. The trade was a 0.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

GLUE has been the topic of a number of recent research reports. Guggenheim lifted their target price on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the company a “buy” rating in a report on Thursday, January 8th. Zacks Research cut shares of Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 4th. Wells Fargo & Company raised their price target on Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, January 8th. Piper Sandler restated an “overweight” rating and issued a $37.00 price target (up previously from $27.50) on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 14th. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.